FTSE 100 firm Reckitt (LSE: RKT) is split into three divisions: health (where key names include Clearasil, Dettol, Durex, Gaviscon, Nurofen and Strepsils); hygiene (Air Wick, Finish, Harpic and Vanish); and nutrition (infant formula brands Enfamil and Nutramigen). The products are leaders in their field and available in 200 countries.
It is difficult to find a company more defensively positioned – more immune to the economic cycle, in other words – anywhere.
Between March 1999 and mid-2017, Reckitt gave shareholders a stunning 12-fold return, even excluding dividends.
Try 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Start your trial
Sign up for MoneyWeek’s free twice-daily newsletter.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Reckitt’s patchy profits
Why, then, have Reckitt shares tumbled by almost 30% since that June 2017 peak? After all, net revenue growth over the five years to the end of December 2021 averaged 8% a year.
Latest Videos FromMoneyWeek
One big fly in the ointment has been the company’s very patchy profits performance. The group’s headline earnings per share (EPS) figures have been all over the place.
Investors are also concerned about competitive pressures as retailers’ own brand products edge in on its market shares.
What’s more, the firm has made several self-inflated errors in recent years.
In 2019, for example, CEO Laxman Narasimhan acknowledged “several areas where we’ve underinvested and overstretched people and assets. At the top line, we’ve had real issues delivering growth, particularly in health”, which “faltered [and] became large, unwieldy and unfocused. We missed important innovations [and] some pricing decisions backfired.”
Investors have moved away from Reckitt shares
So, where does this leave the business now?
Reckitt has just announced third-quarter figures. Group like-for-like (LFL) sales grew by 7.4%, with price rises partly offset by a 4.6% dip in sales volumes.
Despite the challenging global economic climate, Reckitt is pushing ahead.
Interim CEO Nicandro Durante said, “My priority is firmly focused on continuing to… deliver sustainable mid-single digit growth, and mid-20s adjusted operating margins by the mid-2020s.”
As the company gets its act together, Reckitt shares are becoming more appealing.
According to City analysts, the stock is trading at a forward price/earnings (p/e) multiple of 18 for 2022, falling to 16.4 next year. That looks quite cheap for a high-quality growth stock with a portfolio of valuable consumer goods brands.
What’s more, the group has maintained its dividend since 2019. If this pay-out is held steady this year, the prospective yield would be 3%.
For UK investors the firm also has appeal as an international champion. Just 6% of last year’s sales came from the UK, which means its earnings are insulated from sterling volatility. In fact, if the pound continues to depreciate Reckitt’s bottom line would receive a boost.
Reckitt shares are much cheaper today than they were in 2017, and for the past couple of years, the company has deserved a low valuation. But now the firm is getting its house in order, the stock could soon start to regain its former valuation – which in turn would spark a major price rebound.
